Survival impact of surgical cytoreduction in Stage IV epithelial ovarian cancer

Gynecologic Oncology

Volumn 72, Issue 3, 1999, Pages 278-287

  Bristow, Robert E ^a   Montz, Fredrick J ^b   Lagasse, Leo D ^a   Leuchter, Ronald S ^a   Karlan, Beth Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0032980903     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5145     Document Type: Article

References (28)

1. Parker S L, Tong T, Bolden S, Wingo P A. Cancer statistics 1997. CA Cancer J Clin. 47:1997;5-27.
2. International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecological cancer, Stockholm, Panorama Press AB, 1991, 21.
3. Meigs J V. Tumors of the Female Pelvic Organs. 1935;McMillan, New York.
4. Griffiths C T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Monogr Natl Cancer Inst. 42:1975;101-104.
5. Hacker N F, Berek J S, Lagasse L D, Nieberg R K, Elashoff R M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 61:1983;413-420.
6. Hoskins W J, Rubin S C. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol. 18:1991;213-221.
7. Hoskins W J, Bundy B N, Thigpen J T, Omura G A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 47:1992;159-166.
8. Hoskins W J, McGuire W P, Brady M F, Homesley H D, Creasman W T, Berman M, Ball H, Berek J S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 170:1994;974-979.
9. Delgado G, Oram D H, Petrilli E S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 18:1984;293-298.
10. Piver M S, Lele S B, Marchetti D L, Baker T R, Tsukada Y, Emrich L J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol. 6:1988;983-989.
11. Del Campo J M, Felip E, Rubio D, Vidal R Bermejo B, Colomer R, Zanon V. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 53:1994;27-32.
12. Hoskins W J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer. 71:1993;1534-1540.
13. Schwartz P E, Chambers J T, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 53:1994;33-37.
14. Onnis A, Marchetti M, Padovan P, Castelan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol. 17:1996;393-396.
15. Shimizu Y, Hasumi K. Treatment of stage III and IV ovarian cancer - is neoadjuvant chemotherapy effective? Nippon Sanka Fujinka Gakkai Zasshi. Acta obstetrica et Gynaecologica Japonica. 45:1993;1007-1014.
16. Lim J T, Green J A. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (Royal College of Radiologists. 5:1993;198-202.
17. Liu P C, Benjamin I, Morgan M A, King S A, Mikuta J J, Rubin S C. Effect of surgical debulking on survival in Stage IV ovarian cancer. Gynecol Oncol. 64:1997;4-8.
18. Curtin J P, Malik R, Venkatraman E S, Barakat R R, Hoskins W J. Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol. 64:1997;9-12.
19. Munkarah A R, Hallum A V, Morris M, Burke T W, Levenback C, Atkinson E N, Wharton J T, Gershenson D M. Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer. Gynecol Oncol. 64:1997;13-17.
20. Kaplan E, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc. 53:1959;457-481.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
22. Cox D R. Regression models and life tables. JR Stat Soc B. 34:1972;187-202.
23. Goodman H M, Harlow B L, Sheets E E, Muto M G, Brooks S, Steller M, Knapp R C, Berkowitz R S. The role of cytoreductive surgery in the management of Stage IV epithelial ovarian carcinoma. Gynecol Oncol. 46:1992;367-371.
24. Hacker N F. Controversial aspects of cytoreductive surgery in epithelial ovarian cancer. Bailliere's Clin Obstet Gynecol. 3:1989;49-57.
25. Nelson B E, Rosenfield A T, Schwartz P E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 11:1993;166-172.
26. Swenerton K D, Hislop T G, Spinelli J, LeRiche J E, Yang N, Boyes D A. Ovarian carcinoma: a multivariety analysis of prognostic factors. Obstet Gynecol. 65:1985;264-270.
27. Hoskins W J. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Bailliere's Clin Obstet Gynecol. 3:1989;59-71.
28. van der Burg M EL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave A J, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 332:1995;629-634.